Literature DB >> 32981611

Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation.

Ibiayi Dagogo-Jack1.   

Abstract

Entities:  

Year:  2020        PMID： 32981611     DOI： 10.1016/j.jtho.2020.07.007

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

1.  Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers.

Authors:  Yonina R Murciano-Goroff; Terry Pak; Sebastian Mondaca; Jessica R Flynn; Joseph Montecalvo; Natasha Rekhtman; Darragh Halpenny; Andrew J Plodkowski; Stephanie L Wu; Mark G Kris; Paul K Paik; Gregory J Riely; Helena A Yu; Charles M Rudin; Matthew D Hellmann; Josiah D Land; Larry W Buie; Glenn Heller; Piro Lito; Rona Yaeger; Alexander Drilon; Dazhi Liu; Bob T Li; Michael Offin
Journal:  Br J Cancer       Date:  2021-12-28       Impact factor: 9.075

2.  A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker.

Authors:  Alla Turshudzhyan; James Vredenburgh
Journal:  Curr Oncol       Date:  2020-12-25       Impact factor: 3.677

Review 3.  [Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer].

Authors:  Hongxia Zhang; Jinsheng Gao; Wei Guo; Bo Yu; Haitao Yang; Yutao Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-02-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.